Greater Mauritania

Primmune Therapeutics Presents Clinical Data from Phase 1 Study Evaluating PRTX007 in Healthy Volunteers at the 2023 American Association for the Study of Liver Diseases (AASLD) Annual Meeting

Retrieved on: 
Friday, November 10, 2023
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, Greater Mauritania, Hepatology, Safety, Annual general meeting, Therapy, Aes, Hepatitis B virus, Headache, AASLD, SAD, IL-6, Patient, HBV, QOD, TLR7, Pharmacokinetics, Liver, Messenger, Half-life, Șaeș, NK, Vaccine

The data presented highlight the suitability of PRTX007 for investigation as a combination therapy for curative treatment of chronic hepatitis B virus (HBV) infection.

Key Points: 
  • The data presented highlight the suitability of PRTX007 for investigation as a combination therapy for curative treatment of chronic hepatitis B virus (HBV) infection.
  • Data show that PRTX007 demonstrated a favorable safety profile in all of the analyzed cohorts with no serious adverse events (SAEs) observed.
  • “We are encouraged by the results of this Phase 1 study which demonstrate the safety and tolerability of PRTX007 administration in healthy volunteers.
  • CD8+ T cells and NK cell activation (CD38+ markers) increased markedly from pretreatment to end of dosing in all HVs.

Primmune Therapeutics Presents New Clinical Data from Phase 1 Study Evaluating PRTX007 in Healthy Volunteers at the 2023 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Tuesday, April 18, 2023
Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Greater Mauritania, TLR7, AACR, AE, Aes, Pharmacokinetics, IL-6, SAD, NK, Patient, MAD, Entrepreneurship, American Association for Cancer Research, Therapy, Headache, QOD, Vaccine, Pharmaceutical industry

In addition to assessing the clinical safety and tolerability of PRTX007, the study was designed to evaluate the pharmacokinetics of PRTX007 and identify the specific active dosing range for use in future cancer studies.

Key Points: 
  • In addition to assessing the clinical safety and tolerability of PRTX007, the study was designed to evaluate the pharmacokinetics of PRTX007 and identify the specific active dosing range for use in future cancer studies.
  • There were no systemic increases in proinflammatory factors observed for any dose range in the Phase 1 study.
  • Both the clinical characteristics and unique pattern of immune induction by PRTX007 support its use in combination with immune checkpoint inhibitors.
  • Primmune plans to conduct a future study evaluating PRTX007 in combination with a checkpoint inhibitor across the active doses identified in the Phase 1 study for the potential treatment of solid tumors.